BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27402815)

  • 1. Tyrosine receptor kinase B is a drug target in astrocytomas.
    Ni J; Xie S; Ramkissoon SH; Luu V; Sun Y; Bandopadhayay P; Beroukhim R; Roberts TM; Stiles CD; Segal RA; Ligon KL; Hahn WC; Zhao JJ
    Neuro Oncol; 2017 Jan; 19(1):22-30. PubMed ID: 27402815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways.
    Pattwell SS; Arora S; Cimino PJ; Ozawa T; Szulzewsky F; Hoellerbauer P; Bonifert T; Hoffstrom BG; Boiani NE; Bolouri H; Correnti CE; Oldrini B; Silber JR; Squatrito M; Paddison PJ; Holland EC
    Nat Commun; 2020 Jun; 11(1):2977. PubMed ID: 32532995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
    Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
    Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a rare
    Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
    Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Pattwell SS; Konnick EQ; Liu YJ; Yoda RA; Sekhar LN; Cimino PJ
    Case Rep Pathol; 2020; 2020():5903863. PubMed ID: 32082673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma.
    López GY; Perry A; Harding B; Li M; Santi M
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):174-178. PubMed ID: 29804288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
    Jones DT; Hutter B; Jäger N; Korshunov A; Kool M; Warnatz HJ; Zichner T; Lambert SR; Ryzhova M; Quang DA; Fontebasso AM; Stütz AM; Hutter S; Zuckermann M; Sturm D; Gronych J; Lasitschka B; Schmidt S; Seker-Cin H; Witt H; Sultan M; Ralser M; Northcott PA; Hovestadt V; Bender S; Pfaff E; Stark S; Faury D; Schwartzentruber J; Majewski J; Weber UD; Zapatka M; Raeder B; Schlesner M; Worth CL; Bartholomae CC; von Kalle C; Imbusch CD; Radomski S; Lawerenz C; van Sluis P; Koster J; Volckmann R; Versteeg R; Lehrach H; Monoranu C; Winkler B; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; Ebinger M; Schuhmann MU; Cho YJ; Pomeroy SL; von Deimling A; Witt O; Taylor MD; Wolf S; Karajannis MA; Eberhart CG; Scheurlen W; Hasselblatt M; Ligon KL; Kieran MW; Korbel JO; Yaspo ML; Brors B; Felsberg J; Reifenberger G; Collins VP; Jabado N; Eils R; Lichter P; Pfister SM;
    Nat Genet; 2013 Aug; 45(8):927-32. PubMed ID: 23817572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
    Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
    Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA.
    Zhou Y; Sinha S; Schwartz JL; Adami GR
    BMC Cancer; 2019 Jun; 19(1):607. PubMed ID: 31221127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
    Charest A; Wilker EW; McLaughlin ME; Lane K; Gowda R; Coven S; McMahon K; Kovach S; Feng Y; Yaffe MB; Jacks T; Housman D
    Cancer Res; 2006 Aug; 66(15):7473-81. PubMed ID: 16885344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.
    Hu J; Huang Y; Wu Y; Liu F; Sun D; Wang K; Qu H
    Tumour Biol; 2016 Nov; 37(11):15115-15123. PubMed ID: 27662840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas.
    Shamblott MJ; O'Driscoll ML; Gomez DL; McGuire DL
    Cell Commun Signal; 2016 Sep; 14(1):23. PubMed ID: 27659207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours.
    Li Y; Wei C; Wang W; Li Q; Wang ZC
    J Pathol Clin Res; 2023 Mar; 9(2):89-99. PubMed ID: 36533776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of intact hypothalamic and/or hindbrain TrkB signaling leads to perturbations in energy balance.
    Ozek C; Zimmer DJ; De Jonghe BC; Kalb RG; Bence KK
    Mol Metab; 2015 Nov; 4(11):867-80. PubMed ID: 26629410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma.
    Tchougounova E; Kastemar M; Bråsäter D; Holland EC; Westermark B; Uhrbom L
    Oncogene; 2007 Sep; 26(43):6289-96. PubMed ID: 17438529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma.
    Lucas CG; Abdullaev Z; Bruggers CS; Mirchia K; Whipple NS; Alashari MM; Lowichik A; Cheshier S; Phillips JJ; Devine P; Solomon DA; Quezado M; Aldape KD; Perry A
    Acta Neuropathol; 2022 Feb; 143(2):283-286. PubMed ID: 34910220
    [No Abstract]   [Full Text] [Related]  

  • 17. Neurotrophic tyrosine kinase receptor B/neurotrophin 4 signaling axis is perturbed in clinical and experimental pulmonary fibrosis.
    Avcuoglu S; Wygrecka M; Marsh LM; Günther A; Seeger W; Weissmann N; Fink L; Morty RE; Kwapiszewska G
    Am J Respir Cell Mol Biol; 2011 Oct; 45(4):768-80. PubMed ID: 21330466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen induced changes in uterine brain-derived neurotrophic factor and its receptors.
    Wessels JM; Leyland NA; Agarwal SK; Foster WG
    Hum Reprod; 2015 Apr; 30(4):925-36. PubMed ID: 25662808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.